Press Release

GAITHERSBURG, MD and CAMBRIDGE, UK, February 10, 2024 — Revolo Biotherapeutics Limited (“Revolo”) today announced that it will present two posters on its lead candidate, ‘1104, at the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress to be held February 28-March 3, 2025 in San Diego, CA. Presentation Details Format: […]

GAITHERSBURG, MD and CAMBRIDGE, UK, December 12, 2024 — Revolo Biotherapeutics Limited (“Revolo”) today announced new preclinical data demonstrating that subcutaneous (SQ) administration of ‘1104 performed comparably to intravenous (IV) administration in allergen-driven models of atopic dermatitis (AD), effectively reducing key markers of skin inflammation and inflammatory mediators, with excellent local tolerability. “The comparable and consistent response of

GAITHERSBURG, MD and CAMBRIDGE, UK, October 21, 2024 — Revolo Biotherapeutics Limited (“Revolo”) today announced new preclinical data demonstrating the potential of its lead allergic-disease treatment candidate, ‘1104, as a SL formulation. The data shows that when administered sublingually via a dissolvable tablet in a lung model of allergic disease, ‘1104 achieves comparable positive results across multiple inflammatory

GAITHERSBURG, MD and CAMBRIDGE, UK, September 18, 2024 /GlobeNewswire/ — Revolo Biotherapeutics Limited (“Revolo”) today announced new data from preclinical studies that validate atopic dermatitis (AD) as a target indication for the Company’s lead clinical asset, ‘1104. The data reinforces the broad clinical applicability of ‘1104, through a novel upstream mechanism of action (MOA), demonstrating its impact across

GAITHERSBURG, MD and CAMBRIDGE, UK, August 7, 2024 /GlobeNewswire/ — Revolo Biotherapeutics Limited (“Revolo”) today announced that President and Chief Executive Officer, Woody Bryan, Ph.D., will participate in a fireside chat on Wednesday, August 14 at 11:30 a.m. ET at Canaccord Genuity’s 44th Annual Growth Conference being held in Boston at the InterContinental from August 13-15, 2024. Mr.

GAITHERSBURG, MD and CAMBRIDGE, UK, July 24, 2024 /GlobeNewswire/ — Revolo Biotherapeutics Limited (“Revolo”) today announced new data from preclinical studies and previously completed clinical trials that further elucidate the upstream mechanism of action (MOA) of ‘1104, which uniquely affects both the effector and regulatory arms of the immune response. The data confirms that ‘1104 binds to a

GAITHERSBURG, MD and CAMBRIDGE, UK, May 14, 2024 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior remission for patients with autoimmune and allergic diseases, today announced that it will present at two medical meetings in May: The American Thoracic Society (ATS) 2024 International Conference and

GAITHERSBURG, MD and CAMBRIDGE, UK, January 30, 2024 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ‘1104, a first-in-class

– New preclinical data further elucidate ‘1805’s mechanism of action in rheumatoid arthritis (RA) – NEW ORLEANS and CAMBRIDGE, UK, November 7, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that new preclinical

– Treatment with ‘1104 demonstrated a rapid reduction in intradermal allergic inflammation –– Treatment with ‘1104 induced sustained activation of T regulatory and B regulatory cells, providing additional clinical validation of its mechanism of action –   NEW ORLEANS and CAMBRIDGE, UK, October 25, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that